ID: ALA5200118

Max Phase: Preclinical

Molecular Formula: C25H29BrN8O3S2

Molecular Weight: 633.60

Representations

Canonical SMILES:  CNC(=O)[C@]1(C)CC[C@@H](Nc2ncc3c(Br)nn(-c4ccc(-c5nnc(C)s5)c(CCS(C)(=O)=O)c4)c3n2)C1

Standard InChI:  InChI=1S/C25H29BrN8O3S2/c1-14-31-32-22(38-14)18-6-5-17(11-15(18)8-10-39(4,36)37)34-21-19(20(26)33-34)13-28-24(30-21)29-16-7-9-25(2,12-16)23(35)27-3/h5-6,11,13,16H,7-10,12H2,1-4H3,(H,27,35)(H,28,29,30)/t16-,25-/m1/s1

Standard InChI Key:  LSWRRAICGUIZHV-PUAOIOHZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 633.60

Molecular Weight (Monoisotopic): 632.0987

AlogP: 3.71

#Rotatable Bonds: 8

Polar Surface Area: 144.65

Molecular Species: NEUTRAL

HBA: 11

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 2.49

CX LogP: 2.01

CX LogD: 2.01

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.30

Np Likeness Score: -1.01

References

1. Jackson JJ, Shibuya GM, Ravishankar B, Adusumilli L, Bradford D, Brockstedt DG, Bucher C, Bui M, Cho C, Colas C, Cutler G, Dukes A, Han X, Hu DX, Jacobson S, Kassner PD, Katibah GE, Ko MYM, Kolhatkar U, Leger PR, Ma A, Marshall L, Maung J, Ng AA, Okano A, Pookot D, Poon D, Ramana C, Reilly MK, Robles O, Schwarz JB, Shakhmin AA, Shunatona HP, Sreenivasan R, Tivitmahaisoon P, Xu M, Zaw T, Wustrow DJ, Zibinsky M..  (2022)  Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy.,  65  (19.0): [PMID:36127295] [10.1021/acs.jmedchem.2c00736]

Source

Source(1):

• Scientific Literature